Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients

Digestive and Liver Disease

Volumn 39, Issue 1, 2007, Pages 47-51

  Basso, M ^a   Torre, F ^a   Grasso, A ^b   Percario, G ^c   Azzola, E ^d   Artioli, S ^e   Blanchi, S ^a   Pelli, N ^a   Picciotto, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b San Paolo Hospital   (Italy)

^c San Carlo Hospital   (Italy)

^d SANTA CORONA HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic hepatitis C; PEG Interferon; Relapsers; Ribavirin

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HASHIMOTO DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PREDICTION; PRURITUS; QUALITATIVE ANALYSIS; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETREATMENT; RIBAVIRIN; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845879340     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.08.007     Document Type: Article

References (19)

1. Poynard T., Yuen M.F., Ratziu V., and Lai C.L. Viral hepatitis C. Lancet 362 (2003) 2095-2100
2. Papatheodoridis G.V., and Cholongitas E. Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. J Viral Hepat 11 (2004) 287-296
3. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 (1998) 1485-1492
4. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
5. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
6. Carlsson T., Lindahl K., Schvarcz R., Wejstal R., Uhnoo I., Shev S., et al. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. J Viral Hepat 7 (2000) 409-413
7. Weegink C.J., Sentjens R.E., Beld M.G., Dijkgraaf M.G., and Reesink H.W. Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. J Viral Hepat 10 (2003) 174-182
8. Fontana R.J. Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. Gastroenterol Clin North Am 33 (2004) 527-547 viii
9. Halfon P., Khiri H., Tran A., Penaranda G., Courcambeck J., Joly H., et al. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response. Eur J Gastroenterol Hepatol 15 (2003) 1067-1071
10. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
11. Lindsay K.L., Trepo C., Heintges T., Shiffman M.L., Gordon S.C., Hoefs J.C., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34 (2001) 395-403
12. Fried M.W. Viral factors affecting the outcome of therapy for chronic hepatitis C. Rev Gastroenterol Disord 4 (2004) S8-S13
13. Hadziyannis S.J., Sette H., Morgan T., Balan V., Diago M., Marcellin P., et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
14. Zeuzem S., Hultcrantz R., Bourliere M., Goeser T., Marcellin P., Sanchez-Tapias J., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40 (2004) 993-999
15. Meyer-Wyss B., Rich P., Egger H., Helbling B., Mullhaupt B., Rammert C., et al. Comparison Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 13 (2006) 457-465
16. Jacobson I.M., Gonzalez S.A., Ahmed F., Lebovics E., Min A.D., Bodenheimer Jr. H.C., et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 100 (2005) 2453-2462
17. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339 (1998) 1493-1499
18. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 53 (2004) 15-18 Epub 2003 Nov 25
19. Wang Y.S., Youngster S., Grace M., Bausch J., Bordens R., and Wyss D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54 (2002) 547-570